Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 1.00 |
| ▸ | FLT3 | P36888 | 20/20 | 1.00 |
| ▸ | TYK2 | P29597 | 14/20 | 1.00 |
| ▸ | JAK1 | P23458 | 6/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.87 |
| ▸ | CDK2 | P24941 | 12/20 | 0.87 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.87 |
| ▸ | JAK3 | P52333 | 4/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108224 | 0.93 | JAK2 (1.00) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL1108218 | 0.93 | JAK2 (1.00) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL18793219 | 0.89 | JAK2 (0.80) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL1108227 | 0.87 | JAK2 (0.78) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL1108216 | 0.86 | JAK2 (1.00) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL823995 | 0.85 | JAK2 (0.81) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL823977 | 0.85 | JAK2 (1.00) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL1108251 | 0.85 | JAK2 (0.75) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL14538689 | 0.84 | JAK2 (0.72) | JAK2FLT3TYK2JAK1CCNA2 | |
| SCHEMBL1108293 | 0.84 | JAK2 (0.77) | JAK2FLT3TYK2JAK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3854402-A1 | TREATMENT OR PREVENTION OF TRANSPLANT REJECTION | CTI Biopharma Corp. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210069199-A1 | METHODS OF TREATING TRANSPLANT REJECTION | SOBI, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-1951729-B1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CELL THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130172338-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CELL THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172338-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CELL THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8415338-B2 | Oxygen linked pyrimidine derivatives | CELL THERAPEUTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415338-B2 | Oxygen linked pyrimidine derivatives | CELL THERAPEUTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069199-A1 | METHODS OF TREATING TRANSPLANT REJECTION | JAK1, JAK2, JAK3 | JAK2 2/4885FLT3 50/4885TYK2 34/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885TYK2 960/4885 |
| US-20130172338-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885TYK2 960/4885 |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885TYK2 960/4885 |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885TYK2 960/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885TYK2 960/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | JAK2 468/4885FLT3 645/4885TYK2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.